Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
Duurzame remissies met ivosidenib bij IDH1-gemuteerd gerecidiveerd of refractair AML
jul 2018 | Leukemie